Please login to the form below

Not currently logged in
Email:
Password:

BI 655066

This page shows the latest BI 655066 news and features for those working in and with pharma, biotech and healthcare.

Janssen files Stelara follow-up guselkumab in Europe

Janssen files Stelara follow-up guselkumab in Europe

AZ) MEDI2070 candidate, tildrakizumab from Sun Pharma (formerly MSD) and Boehringer Ingelheim/AbbVie's BI 655066, all of which are still in clinical trials.

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Acquisition - company. $600. Boehringer Ingelheim/ AbbVie. BI-655066: anti-IL-23 MAb in Phase III for psoriasis and other autoimmune disorders; and BI-655064: anti-CD-40 MAb in Phase I.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics